Solid operational growth and improved profitability were achieved in H1 2026, with strong cash flow and robust demand for consumables. Guidance for full-year revenue and margin was confirmed, while tariff-related effects and delayed advanced therapy orders remain key uncertainties.Based on Sartoriu…
Solid operational growth and improved profitability were achieved in H1 2026, with strong cash flow and robust demand for consumables and equipment. Guidance for full-year revenue and margin was confirmed, despite tariff-related volatility and isolated delays in advanced therapies.Based on Sartoriu…
Operational sales revenue grew 7.7% in constant currencies, driven by recurring consumables and stabilization in equipment and instruments. Underlying EBITDA margin improved to 30.3%, and management confirmed full-year guidance despite tariff-related impacts.Original document: Sartorius AG [SRT] Ea…
Profitable growth continued in H1 2026, led by high-margin consumables and services, with all regions contributing. Underlying EBITDA and net profit rose, and management confirmed full-year guidance despite technical impacts from U.S. tariff refunds and compensation. Asia/Pacific showed the stronge…
